Johnson & Johnson (NYSE:JNJ) reported first-quarter results Tuesday that exceeded analyst expectations and raised its full-year 2026 outlook.
The company posted adjusted earnings per share of $2.70, surpassing the consensus estimate of $2.68. Revenue totaled $24.1 billion, exceeding expectations of $23.61 billion and increasing 9.9% from $21.9 billion in the prior-year period.
Johnson & Johnson raised its full-year adjusted EPS guidance to a range of $11.45 to $11.65, with a midpoint of $11.55 in line with analyst expectations. The company also projected full-year reported sales between $100.3 billion and $101.3 billion, with the midpoint slightly above the consensus estimate of $100.65 billion.
The updated outlook represented an increase from the company’s prior guidance issued in January. Shares were slightly lower following the announcement.
Growth was led by the Innovative Medicine segment, which recorded worldwide operational sales growth of 7.4%. Key contributors included DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in oncology, as well as TREMFYA in immunology and SPRAVATO in neuroscience. These gains were partially offset by declines in STELARA and IMBRUVICA.
The MedTech segment delivered operational sales growth of 4.6%, driven by strength in electrophysiology, Abiomed, Shockwave cardiovascular products, and trauma-related orthopaedic offerings.
